Evidence map›Paper›PMID 39452183›Full record

ArticleAntibiotics (Basel, Switzerland)2024

Phage-Antibiotic Combination Therapy against Recurrent

Ulla Elina Otava, Laura Tervo, Riikka Havela, Liisa Vuotari, Matti Ylänne, Annette Asplund, Sheetal Patpatia, Saija Kiljunen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Antibiotics (Basel, Switzerland) · 2026
    Article
  2. StudiesAntimicrobial agents and chemotherapy · 2025
    Article
  3. [Potential of bacteriophage therapy in Germany: evidence and clinical relevance].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025
    Review
  4. Article
  5. Multidrug-resistantFrontiers in microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ulla Elina OtavaDepartment of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland.ORCID 0000-0002-8772-628X
Laura TervoDepartment of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland.ORCID 0000-0001-9474-0285
Riikka HavelaDepartment of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland.ORCID 0000-0002-3683-0343
Liisa VuotariFaculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland.
Matti YlänneHuman Microbiome Research Program, Research Programs Unit and Medicum, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.ORCID 0000-0003-0832-6913
Annette AsplundHuman Microbiome Research Program, Research Programs Unit and Medicum, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.
Sheetal PatpatiaHuman Microbiome Research Program, Research Programs Unit and Medicum, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.ORCID 0000-0002-7206-5394
Saija KiljunenHuman Microbiome Research Program, Research Programs Unit and Medicum, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.ORCID 0000-0003-0461-7270

Funding

Jane and Aatos Erkko Foundation n.a.Research Council of Finland 336519Research Council of Finland PROFI7
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

arterial stentmeropenemneutropeniaphage therapyPseudomonas aeruginosasepticemia

Identifiers

PMID39452183
PMCPMC11504013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.